Detalles de la búsqueda
1.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica
; 109(2): 553-566, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646664
2.
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.
Hematol Oncol
; 42(3): e3278, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38726682
3.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Am J Hematol
; 98(2): 300-308, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36588409
4.
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Haematologica
; 106(6): 1608-1615, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32414849
5.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407608
6.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196165
7.
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Am J Hematol
; 96(11): 1374-1384, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34324220
8.
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
Cancer
; 126(6): 1235-1242, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31821549
9.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer
; 126(2): 293-303, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31568564
10.
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy.
Br J Haematol
; 189(2): 313-317, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31804715
11.
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Blood
; 132(15): 1568-1572, 2018 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30111609
12.
Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model.
Ann Behav Med
; 53(9): 839-848, 2019 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30590383
13.
Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.
Cancer
; 124(15): 3240-3248, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29757455
14.
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Br J Haematol
; 180(2): 259-266, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29193006
15.
Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
Ann Behav Med
; 52(4): 287-298, 2018 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30084895
16.
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Cancer
; 123(22): 4411-4418, 2017 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28749548
17.
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Blood
; 126(7): 842-50, 2015 Aug 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-26116658
18.
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study.
Haematologica
; 106(10): 2774-2778, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34233448
19.
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
Cancer
; 120(11): 1677-85, 2014 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24578014
20.
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Blood Adv
; 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38781315